Ucb Pharma is an API and finished-dose manufacturer based in Belgium. It holds 2 active US drug master files. Its filings concentrate with MHRA (UK), AIFA (IT) and FAMHP (BE). Its GMP standing is certified by MHRA (UK), ZLG (DE) and NAFDAC (NG), among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 1 February 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Braine-l'Alleud, United Arab Emirates | Not on file |
| Braine-L'Alleud, Belgium | Not on file |
| BRAINE-L'ALLEUD, Belgium | Not on file |
| Braine-Lalleud, Belgium | Not on file |
| Braine-L'Alleud, Belgium | Not on file |
| Belgium, Belgium | 3003909356 |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Cetirizine | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MHRA (UK) | 378 | 8 |
| AIFA (IT) | 258 | None |
| FAMHP (BE) | 206 | None |
| EMA | 102 | 3 |
| US FDA | 78 | 2 |
| MPA (SE) | 74 | None |
| ZLG (DE) | None | 4 |
| NAFDAC (NG) | None | 3 |
| ANVISA (Brazil) | None | 3 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2019 | $3.2B | Not reported | Not reported |
| 2012 | $1.1B | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Ucb Pharma comes back tiered against every other supplier able to file there.
Start for free